What is the published evidence for patient symptom self-reporting in oncology?

Patient self-reporting of symptoms during oncology treatment is associated with a 22.5 vs 14.9 months median overall survival benefit (Denis et al., JAMA 2019), a 31% vs 41% reduction in emergency room visits (Basch et al., J Clin Oncol 2016), and downstream reductions in hospitalisation and chemotherapy interruptions. The survival benefit is larger than most oncology drugs produce. Care Journal is built to operationalise this evidence inside structured CTCAE grading.